What Is Jeuveau? Results, Duration, Safety & How It Compares

Jeuveau entered the U.S. market in 2019 and quickly became known as “Newtox.” That nickname is useful for recognition, but it can also make Jeuveau sound more fundamentally different from other wrinkle relaxers than the evidence supports. It belongs to the same general drug class as Botox, Dysport and Xeomin, while remaining a separate prescription product with its own formulation, labeling and potency units.

What Is Jeuveau?

Jeuveau is the brand name for prabotulinumtoxinA-xvfs. Like other botulinum toxin type A products, it reduces release of acetylcholine at the neuromuscular junction. Acetylcholine is the chemical messenger a nerve uses to tell a muscle to contract.

When a selected facial muscle contracts less strongly, the skin over that muscle is folded less aggressively. That is why neuromodulators are most useful for dynamic wrinkles, lines created or deepened by repeated facial movement.

Jeuveau is not a dermal filler. It does not add facial volume, physically fill a crease or replace lost structural support.

What Is Jeuveau FDA Approved to Treat?

The current U.S. prescribing information is narrow and specific: Jeuveau is indicated for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity in adults.

Those are the vertical frown lines that appear between the eyebrows, often called the “11s.”

Off-label use does not automatically mean inappropriate. It means the FDA-approved labeling for that exact drug does not include that specific indication.

Jeuveau vs. Botox: What Does the Evidence Actually Show?

Jeuveau and Botox Cosmetic are separate botulinum toxin type A products. Jeuveau contains prabotulinumtoxinA-xvfs. Botox contains onabotulinumtoxinA.

A large randomized Phase III trial directly compared 20 units of prabotulinumtoxinA with 20 units of onabotulinumtoxinA for moderate to severe glabellar lines. At day 30, investigator-rated responder rates were 87.2% with prabotulinumtoxinA and 82.8% with onabotulinumtoxinA. The trial met its predefined criteria for noninferiority.

That supports Jeuveau as an effective treatment for its approved glabellar indication. It does not prove that Jeuveau is universally stronger, more natural, faster or better than Botox for every facial area.

Does Jeuveau Work Faster Than Botox?

Jeuveau is frequently marketed as a fast-onset toxin. Some patients do notice early changes within the first several days, but current comparative evidence does not justify saying Jeuveau always works faster than Botox.

A small randomized, triple-blind split-face study compared prabotulinumtoxinA and onabotulinumtoxinA in 15 patients. Investigators found no statistically significant difference in onset of action, wrinkle appearance or patient satisfaction between the two products.

When Do Jeuveau Results Appear?

Jeuveau does not create its full effect immediately after injection. Muscle activity gradually decreases as the medication begins affecting neuromuscular signaling.

The exact timeline varies. A treatment should not be judged solely by how much movement has changed on day two or day three.

How Long Does Jeuveau Last?

For many patients, the practical treatment interval falls around three to four months, although duration varies. The prescribing information states that Jeuveau retreatment should be given no more frequently than every three months.

Clinical research also shows that some patients can maintain a measurable effect longer than three months.

A 2024 randomized trial comparing 20 units of Jeuveau with 20 units of Botox found median return-to-baseline durations of approximately 149 days for Jeuveau and 148 days for Botox using investigator-rated glabellar line severity. That was one defined clinical-trial endpoint, not a guarantee that either treatment will last nearly five months in every patient.

Are Jeuveau Units the Same as Botox Units?

The number printed on the syringe may look comparable, especially because both Jeuveau and Botox use a 20-unit FDA-labeled dose for glabellar lines. That does not create a universal unit-conversion rule.

Jeuveau’s prescribing information is explicit: its potency units are specific to its preparation and assay method and cannot be compared with or converted into the units of other botulinum toxin products.

The correct dose therefore starts with the selected product, the muscle being treated and that product’s evidence and labeling. Patients should not try to translate an old Botox dose directly into Jeuveau units on their own.

What About Forehead Lines, Crow’s Feet and Other Areas?

Jeuveau is commonly used by experienced injectors in facial areas beyond the glabella, but those treatments are off-label under the current U.S. indication.

This matters because the clinical evidence, FDA labeling and approved dosing are strongest for the glabellar region. Treatment elsewhere requires a provider to make an individualized decision based on anatomy and the intended effect.

Can You Switch From Botox to Jeuveau?

Yes. Patients sometimes change neuromodulator brands because of prior response, provider preference, pricing, availability or simply because they want to compare their own experience.

The provider should know exactly what was used previously, how much was injected, where it was placed and when treatment occurred. Referring to every prior neuromodulator treatment simply as “Botox” can make that history less useful.

Switching products also does not mean the new treatment should automatically copy the old injection pattern or dose. Each treatment should be planned using the selected product and the patient’s current anatomy.

Jeuveau Risks and Safety

Jeuveau is a prescription botulinum toxin medication and carries a boxed warning regarding the possibility of toxin effects spreading beyond the injection site.

Serious symptoms described in botulinum toxin labeling can include generalized weakness, double vision, drooping eyelids, difficulty speaking or swallowing and breathing problems. Such symptoms can occur hours to weeks after injection.

Localized cosmetic side effects can include bruising, discomfort, headache, temporary eyelid droop, asymmetry or unwanted weakness of a nearby muscle.

Who Should Not Receive Jeuveau?

Jeuveau is contraindicated in people with known hypersensitivity to botulinum toxin preparations or any of its formulation components and in the presence of infection at the proposed injection site.

Extra caution is appropriate in people with neuromuscular disorders or other conditions that may increase sensitivity to botulinum toxin effects. Patients should tell the provider about previous botulinum toxin treatment and medications that may interfere with neuromuscular transmission.

Pregnancy and breastfeeding should also be discussed before elective cosmetic treatment because available human safety data are limited.

So Is Jeuveau Better Than Botox?

There is no strong evidence that makes Jeuveau universally better than Botox.

For FDA-approved glabellar treatment, a large Phase III trial demonstrated that 20 units of prabotulinumtoxinA were noninferior to 20 units of onabotulinumtoxinA. Smaller comparative research has not established a consistent onset advantage for Jeuveau.

Botox currently has more FDA-approved cosmetic treatment areas in the United States. Jeuveau is focused on the glabellar indication and has become another legitimate option for patients and injectors who prefer it.

Neither column establishes medical superiority. Product choice is only one part of a good result. Anatomy, dose, placement and injector judgment remain critical.

For a deeper comparison of the main toxin brands, see the Skin Works wrinkle relaxer comparison. Current Jeuveau pricing, treatment information and appointment options are available on the dedicated Jeuveau in Torrance service page.

Frequently Asked Questions